Buprenorphine Transdermal Patch Microreservoir Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current transdermal therapeutic systems (TTS) for buprenorphine administration face challenges in maintaining consistent drug release rates over seven days, leading to skin irritation and excessive drug amounts, which can be subject to illicit use and waste, while also requiring larger sizes and higher doses to sustain delivery.
Innovation Solution
A microreservoir system with buprenorphine and carboxylic acid dispersed in a hydrophobic pressure-sensitive adhesive layer, incorporating a viscosity-increasing substance like polyvinylpyrrolidone, to form dispersed deposits that control drug release and reduce system size and drug content, ensuring reproducible and sustained pain relief for seven days.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If a large area of release and high drug content are used to sustain delivery over seven days, then the duration of action is improved, but the skin irritation and illicit use risk increase
Solution Approach 1:
The patent segments the drug reservoir into discrete microcapsules (1-10 μm diameter) dispersed throughout the adhesive layer. This segmentation allows the drug to be released in controlled amounts from numerous small units rather than from a large continuous reservoir, maintaining prolonged duration of action while reducing the concentration of drug at any single location, thereby reducing skin irritation and illicit use risk.
2Duration of action of stationary object
If a large area of release is used to sustain delivery over seven days, then the duration of action is improved, but the device size increases
Solution Approach 1:
The patent changes the physical parameters of the drug reservoir by using microcapsules with diameters of 1-10 μm instead of large continuous reservoirs. This parameter change in the scale and distribution of the drug-containing structures enables sustained release over seven days from a much smaller overall device area, as the high surface-area-to-volume ratio of the microcapsules enhances release efficiency while minimizing the total area required.
3Duration of action of stationary object
If a large amount of excess drug is included to sustain delivery over seven days, then the duration of action is improved, but the illicit use potential and waste increase
Solution Approach 1:
The patent incorporates a viscosity-increasing substance in the adhesive layer before drug delivery begins. This preliminary action of increasing viscosity prevents excessive drug migration and leakage during storage and application, ensuring that the drug is released only as intended through controlled transdermal delivery. This eliminates waste from premature drug loss while maintaining sufficient drug quantity for the full seven-day duration of action.
4Area of stationary object
If dispersed deposits are used to reduce system size and drug content, then the area of release is reduced, but the manufacturing precision becomes more challenging
Solution Approach 1:
The patent introduces a viscosity-increasing substance as an intermediary component in the adhesive layer. This intermediary substance controls the formation and stabilization of microcapsule deposits during manufacturing, preventing aggregation and ensuring uniform size distribution. By mediating the interaction between the dispersed drug particles and the adhesive matrix, this substance enables precise control of deposit characteristics while maintaining reduced system size and area of release.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system achieves high and reproducible release rates of buprenorphine over seven days, reducing skin irritation, drug waste, and illicit use risks, while maintaining a smaller size and lower drug amounts, thus enhancing patient compliance and treatment efficacy.
Implementation Method 1
a carboxylic acid selected from the group consisting of oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof, in an amount sufficient so that said analgesically effective amount of buprenorphine is solubilized therein to form a mixture
Implementation Method 2
a viscosity-increasing substance in an amount of about 0.1% to about 8% of said buprenorphine-containing pressure-sensitive adhesive layer
Implementation Method 3
The system achieves high and reproducible release rates of buprenorphine over seven days
Data Source
AI summary
A transdermal therapeutic system for the transdermal administration of buprenorphine comprising a buprenorphine-containing self-adhesive layer structure having (A) a buprenorphine-impermeable backing layer, and (B) a buprenorphine-containing pressure-sensitive adhesive layer on the backing layer. The buprenorphine-containing adhesive layer comprises (a) at least one polymer-based pressure-sensitive adhesive, (b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, (c) a viscosity-increasing substance in an amount of about 0.1% to about 8% of the buprenorphine-containing pressure-sensitive adhesive layer, and (d) a carboxylic acid selected from oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof. The amount of the carboxylic acid is sufficient so that the analgesically effective amount of buprenorphine is solubilized in the carboxylic acid to form a mixture including the viscosity-increasing substance. This mixture forms dispersed deposits in the pressure-sensitive adhesive. The buprenorphine-containing pressure-sensitive adhesive layer is the skin contact layer.